Cell free DNA (cfDNA) screening could significantly reduce colon cancer deaths if patient participation increases.
A groundbreaking Canadian study explores how cfDNA testing could revolutionize colon cancer screening. Improved survival rates, better patient compliance, and real economic value, this test could soon replace outdated methods. But it all hinges on one critical factor: participation. Here’s what the study uncovered—and why it matters more than ever(1✔ ✔Trusted Source
Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada
Go to source
).
Why cfDNA Screening Matters
cfDNA is a novel, non-invasive blood test that detects colon cancer markers early—potentially even before symptoms appear. This method has already been approved in the US, and Canadian researchers are now testing its feasibility for nationwide use. Unlike
fecal-based
What the Canadian Study Found
Using the OncoSim-Colorectal model, researchers simulated a population of 32 million Canadians over nearly 70 years. If participation rates were high, cfDNA could detect over 393,000 cancer cases, reducing mortality rate by 121,383 compared to current fecal-based tests. But here’s the catch: without increased participation, the benefits diminish. The study showed that cfDNAcould cost CAD $234.80 per health-adjusted person-year gained, which is cost-effective considering its life-saving potential.
The Price of Progress – Is It Worth It?
Though cfDNA testing comes with a higher upfront cost, it delivers a better return in health outcomes. For every CAD $100,000 (US $69,874) spent beyond FIT, 025 lives are saved. That might sound small, but when scaled to millions, it’s a powerful impact. Crucially, the test’s success relies on increased participation, ideally 78% or higher. Without this, it performs worse than colonoscopy or FIT (fecal immunochemical testing), emphasizing the need for strong public outreach and education.
Why Patient Participation Is the Real Game-Changer
The study made one thing crystal clear: even the best screening method won’t save lives if people don’t use it. While cfDNA tests are more convenient and less invasive than traditional stool-based tests, their success depends heavily on public participation. The model showed that 43% participation yields worse outcomes than current methods. That means to unlock the life-saving benefits of cfDNA, education, awareness, and accessibility must improve. Patients’ preference for blood vs. stool-based tests could make or break its real-world impact.
References:
- Modeling Population-Level Impacts of Cell-Free DNA Screening for Colorectal Cancer in Canada
– (https://jamanetwork.com/journals/jamaoncology/article-abstract/2833397)
Source-JAMA Oncology